** Shares of Pittsburgh-based drug developer Lipella Pharmaceuticals LIPO.O rise 68.20% to $5.14 premarket
** LIPO says its experimental drug, LP-310, showed a strong safety profile in a small study of 24 patients with oral lichen planus $(OLP)$, a chronic inflammatory disease that affects mucous membranes inside the mouth
** Co says no drug-related serious adverse events were found in study, and no patients dropped out
** LIPO says LP-310, an oral rinse topical treatment, helped meaningfully reduce pain, ulceration, and inflammation for patients in the study
** Co plans to submit marketing application for LP-310 to the FDA in H2 2025
** In the last 12 months, the stock has fallen 63.34%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。